CBD and Ibuprofen: One Shared Liver Enzyme

One liver, two molecules

Ibuprofen is a medicine. CBD, in the form we sell it, is a food supplement. Two different shelves, two different sets of rules. Once either one is inside you, though, the same organ does the work. The liver.

A large share of what the body breaks down goes through a group of enzymes called cytochrome P450. Not one protein. A family, with dozens of members, each carrying its own name and its own list of molecules it acts on. Pharmacology has been mapping those lists for decades. That mapping is the reason a package leaflet can say anything useful about interactions at all.

Ibuprofen sits in a tidy corner of that map. Its clearance runs mainly through one liver enzyme, cytochrome P450 2C9, written CYP2C9 in the research literature. One enzyme, one main route out.

Cannabidiol was mapped later. Jiang and colleagues, in work published in 2011, set out to identify which cytochrome P450 enzymes are responsible for metabolising cannabidiol [1]. The system was human liver microsomes: prepared fractions of liver tissue, used in the lab as the standard way to ask which enzyme acts on which compound. What came out of it was straightforward rather than dramatic. Cannabidiol is processed by the same broad enzyme family that processes a long list of everyday medicines [1].

So there is the overlap, stated plainly. Ibuprofen leans on one member of that family. CBD is processed by members of the same family [1]. That is a shared address, not a measured event. Nothing in the 2011 work describes what happens when the two turn up together, because that was never the question being asked [1]. It named enzymes in a laboratory system. It did not follow a person taking a supplement and a painkiller on the same afternoon.

Worth holding on to: an enzyme map shows the road, not the traffic on it. Microsomes are liver tissue in a tube. They tell you which enzyme is capable of acting on cannabidiol, at the concentrations the experiment chose [1]. They say nothing about how much cannabidiol reaches a liver after a few drops of oil, and they were never built to. Same family, different questions. That is where a lot of the confusion around this topic starts.

What the 2019 review flags

The second paper is a review rather than a bench experiment. Brown and colleagues, publishing in 2019, went through the record on potential adverse drug events and interactions across both medical and consumer use of cannabidiol [2]. That second word matters. Consumer use means supplements, bought off a shelf, taken without a prescription.

Their reading of the literature describes cannabidiol as an inhibitor of several cytochrome P450 enzymes, and the enzyme that clears ibuprofen is among them [2]. Inhibition, here, means the enzyme's capacity is occupied or slowed. The mechanism the review puts forward is competition: two compounds arriving at the same clearance enzyme, with a finite amount of enzyme to go around [2].

From that mechanism follows a flag, and the flag is written in groups rather than brand names. What gets named are substrates, meaning the molecules that depend on the enzymes listed as inhibited [2]. Ibuprofen belongs to one of those groups [2]. The review is not commenting on any particular bottle, any particular batch, or any particular amount.

Sitting next to it in the same literature is the 2017 safety review by Iffland and Grotenhermen, which gathered what was then known about the side effects of cannabidiol and pointed out where the human data was thin. Read together, the two reviews sketch one shape: a compound with a mapped route through the liver, and a set of open questions about what happens in combination.

• The enzyme in question: cytochrome P450 2C9, the main clearance route for ibuprofen, and one of several enzymes described as inhibited by cannabidiol in the 2019 review [2].
• Ibuprofen's status: a substrate of that enzyme, which is exactly what places it inside the flagged group rather than outside it [2].
• The mechanism proposed: competition for one shared clearance enzyme, not some new reaction between the two molecules themselves [2].
• The scope of the flag: substrate groups, named at the level of pharmacology, with no product, format or dose attached [2].
• Other groups on the same list: substrates of the other cytochrome P450 enzymes the review names among those inhibited [2].
• The strength of the wording: theoretically possible, which is a plainly different claim from measured in people [2].

Where the record runs out

Two things are documented. First, the cytochrome P450 enzymes that metabolise cannabidiol in human liver microsomes have been identified [1]. Second, a 2019 review describes cannabidiol as an inhibitor of several of those enzymes and places their substrates in a group where an interaction is theoretically possible [2]. Ibuprofen is in that group [2].

One thing is not documented. Nobody has published a study that follows people taking a CBD food supplement, at supplement amounts, alongside ibuprofen, and measures what happens to either. That row of the record is empty.

Empty is not the same as safe. It is also not the same as risky. An absence of study is an absence of information, and saying flatly that no interaction is possible would be as unsupported as promising that one is. We have been working with cannabinoids since 2014, and if that time teaches anything, it is restraint at exactly this point. Where the evidence stops, the sentence stops too.

What we can be exact about is the bottle. Our CBD oil 2.0 and CBD capsules 2.0 are sold as food supplements. Not medicines. That classification is deliberate rather than modest, and it marks the limit of what a product page can reasonably do. A page cannot see your prescription list, the amounts on it, or the reason you reach for ibuprofen in the first place.

A pharmacist or a doctor can see all of that. Bring the full medication list, the CBD product included, and ask about the enzyme overlap directly, by name. Short conversation. Specific answer. More than any article gets to give you.

Contents are our department. Production runs from Schijndel to a Swiss standard, independently since 2014, and every batch is analysed, so what is in the bottle can be checked instead of assumed. Cannabinoid content, verified per batch. That is a different kind of certainty from a pharmacological one, and the two are worth keeping apart.

The short version: one shared clearance enzyme [2], one theoretical flag from a 2019 review [2], one professional conversation that carries more weight than anything written here. That shape has not changed since Jiang and colleagues named the enzymes back in 2011 [1]. Research keeps moving, and when the record fills in, the wording on this page moves with it.

The cited work, row by row